Cargando…

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo, Kenichiro, Kawakado, Keita, Kawajiri, Tomoka, Nishi, Tatsuya, Makimoto, Go, Tamura, Tomoki, Kuyama, Shoichi, Tanimoto, Mitsune
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434540/ https://www.ncbi.nlm.nih.gov/pubmed/32296006 http://dx.doi.org/10.2169/internalmedicine.4449-20

Ejemplares similares

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Transcatheter embolization for idiopathic peripheral pulmonary arterial aneurysm: A case report
por: Tamura, Tomoki, et al.
Publicado: (2019)

Successful transcatheter arterial embolization of asymptomatic aneurysm associated with left inferior phrenic artery-to-left pulmonary artery fistula: A case report
por: Kawakado, Keita, et al.
Publicado: (2021)

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
por: Makimoto, Go, et al.
Publicado: (2021)

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
por: Kawakado, Keita, et al.
Publicado: (2021)

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
por: Tamura, Tomoki, et al.
Publicado: (2021)

Successful corticosteroid treatment of necrotizing sarcoid granulomatosis associated with tracheal lesion recurred after a surgical lung biopsy
por: Makimoto, Go, et al.
Publicado: (2021)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
por: Kawakado, Keita, et al.
Publicado: (2021)

Heerfordt's Syndrome Associated with Trigeminal Nerve Palsy and Reversed Halo Sign
por: Makimoto, Go, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
por: Tamura, Tomoki, et al.
Publicado: (2021)

Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study
por: Harada, Daijiro, et al.
Publicado: (2022)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
por: Morita, Ayako, et al.
Publicado: (2021)

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
por: Tamura, Shuzo, et al.
Publicado: (2018)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2015)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
por: Zhou, Tao, et al.
Publicado: (2022)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

A case of synovitis-acne-pustulosis-hyperostosis-osteitis syndrome with right pleural effusion
por: Kakimoto, Takayuki, et al.
Publicado: (2023)

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer
por: Mizusaki, Shun, et al.
Publicado: (2020)

OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma
por: Yekula, Anudeep, et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients
por: Yekula, Anudeep, et al.
Publicado: (2023)

A case of immunoglobulin G4-Related disease with pleural effusion, requiring exclusion of tuberculous pleurisy
por: Doita, Susumu, et al.
Publicado: (2022)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
por: Wilson, George D., et al.
Publicado: (2020)

Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry
por: Yamamoto, Yutaro, et al.
Publicado: (2019)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
por: Fostvedt, Luke K., et al.
Publicado: (2022)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
por: Li, Hong‐Shuai, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
por: Zhang, Longfeng, et al.
Publicado: (2021)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Drug-induced liver injury associated with dacomitinib: A case report
por: Wang, Xuanxuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_08pdtfm1duavgvu55o89umsvl2